ToleroMune® allergy immunotherapies publications
Creticos P. World Allergy Org J 2014;7:30. Advances in synthetic peptide immuno-regulatory epitopes. (PDF)
Couroux P, et al. Clinical & Experimental Allergy 2015;45:974-981. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects
Hafner et al. Clinical and Translational Allergy 2013, 3(Suppl 2):07. Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat-PAD, the first in a new class of synthetic peptide immuno-regulatory epitopes. (PDF)
Worm M, et al. Expert Opin. Investig. Drugs (2013) 22(10):1347-1357. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis.
Patel D, et al J Allergy Clin Immunol 2013;131:103-9. Fel d 1–derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study
Larche M, et al. EAACI 2012 Abstract. Safety and efficacy of Fel d 1 derived peptide immunotherapy in a double-blind, placebo-controlled environmental exposure chamber study (PDF)
Worm M, et al. J Allergy Clin Immunol 2011;127:89-97. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy.
Larche M. et al. JEM:2009 (7);1535-1547. Peptide immunotherapy in allergic asthma generates IL-10–dependent immunological tolerance associated with linked epitope suppression.
House dust mite SPIRE
Larche, et al. J Allergy Clin Immunol. Volume 131, Number 2. Safety and Tolerability of Escalating Doses of House Dust Mite- Peptide Antigen Desensitization (HDM-PAD) (PDF)
R. P. Hafner, et al. J Allergy Clin Immunol. Feb. 2012. Validation of Peptide Immunotherapy as a New Approach in the Treatment of Allergic Rhinoconjunctivitis: The Clinical Benefits of Treatment with Amb a 1 Derived T cell Epitopes. (PDF)
Visit the publications section for more publications related to our other technologies.